Elotuzumab (anti-SLAMF7) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to SLAMF7, >95%, high purity, Human IgG1, Antibody of CS1 (CD319)
Elotuzumab (anti-SLAMF7) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to SLAMF7, >95%, high purity, Human IgG1, Antibody of CS1 (CD319)
Elotuzumab (anti-SLAMF7) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to SLAMF7, >95%, high purity, Human IgG1
Elotuzumab is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity. Purity >95% (SDS-PAGE&SEC) Endotoxin Level<0.01EU/μg
Product Properties
Antibody Type
Primary antibody
Clonality
Recombinant
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
27.1 kDa (Light Chain) & 52.3 kDa (Heavy Chain), under reducing conditions; 173.0 kDa, under non-reducing conditions.
Purification Method
Protein A purified
Purity
>95%
Source
CHO supernatant
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
915296-00-3
Images
Elotuzumab (anti-SLAMF7) (Ab169272) - ELISA Immobilized huSLAMF7-Fc at 2 μg/mL can bind Elotuzumab (anti-SLAMF7) (Ab169272) with the EC₅₀ of 18.15 ng/mL.
Elotuzumab (anti-SLAMF7) (Ab169272) - SEC The purity of Elotuzumab (anti-SLAMF7) (Ab169272) is more than 95% verified by HPLC.
1.Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG et al.. (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.. Blood, 112 (4):(1329-37). [PMID:17906076]
2.Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y et al.. (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.. Clin Cancer Res, 14 (9):(2775-84). [PMID:18451245]
3.van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R et al.. (2009) Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.. Mol Cancer Ther, 8 (9):(2616-24). [PMID:19723891]
4.Veillette A, Guo H. (2013) CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.. Crit Rev Oncol Hematol, 88 (1):(168-77). [PMID:23731618]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
ZJ24F0303033